<DOC>
	<DOC>NCT01725386</DOC>
	<brief_summary>This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (XelodaÂ®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.</brief_summary>
	<brief_title>An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult female participants, &gt;/= 18 years of age Cytologic/histopathologic confirmed diagnosis of metastatic breast cancer Prescribed capecitabine as in routine clinical practice Informed consent signed Participation in any other clinical trial History of severe and unexpected reactions to fluoropyrimidine therapy Hypersensitivity to capecitabine or to any of the excipients of fluorouracil Known dihydropyrimidine dehydrogenase (DPD) deficiency Pregnant or lactating women Severe leucopenia, neutropenia, or thrombocytopenia Severe hepatic impairment Severe renal impairment (creatinine clearance below 30 ml/min) Treatment with sorivudine or its chemically related analogues, such as brivudine Refusal to give consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>